MOR 14

Drug Profile

MOR 14

Alternative Names: N-methyldeoxynojirimycin; N-methylmoranoline

Latest Information Update: 13 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nippon Shinyaku
  • Class Anti-ischaemics; Antihyperglycaemics; Antithrombotics; Small molecules
  • Mechanism of Action Alpha-glucosidase inhibitors; Plasmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arterial thrombosis; Diabetes mellitus; Reperfusion injury

Most Recent Events

  • 25 May 1998 Preclinical development for Reperfusion injury in Japan (Unknown route)
  • 25 May 1998 A study has been added to the Ischaemic Heart Disease pharmacodynamics section
  • 03 Oct 1995 Discontinued-Preclinical for Arterial thrombosis in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top